Year
2025202420232022202020192018201720162015201420132012201120102009200820072006200520042003200220012000
Edition number
№11 / 2021
REVIEWS
F.V. Moiseenko (1, 2)
Hope or error: can combinations of EGFR tyrosine kinase inhibitors and other drugs replace monotherapy?13-20
E.A. Kobyakova (1), D.Yu. Usachev (2), O.V. Absalyamova (2), N.G. Kobyakov (3), K.S. Lodygina (2), A.Yu. Belyaev (2), Yu.Yu. Trunin (2), A.S. Belyashova (2), G.L. Kobyakov (2)
Response assessment in neuro-oncology (RANO) criteria: application in clinical research and routine practice21-33
D.A. Sychev (1), O.D. Ostroumova (1), M.S. Chernyaeva (2), A.P. Pereverzev (1), A.I. Kochetkov (1), T.M. Ostroumova (3), M.V. Klepikova (1), E.Yu. Ebzeeva (1), V.A. De (1)
Risk factors of drug-induced diseases. Part 1. Classification, non-modified risk factors34-46
A.S. Kulakova, D.L. Bentsion, V.G. Elishev, V.A. Vetrov
Systemic alpha-radiotherapy with radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC). Clinical experience of using the drug in Sverdlovsk Regional Oncological Dispensary, Yekaterinburg47-51
A.I. Semenova (1), S.A. Protsenko (1), G.M. Teletaeva (1), D.Kh. Latipova (1), A.V. Novik (1, 2)
Neoadjuvant immunotherapy for non-small cell lung cancer52-56
L.G. Zhukova (1), E.V. Artamonova (2, 3, 4), I.P. Ganshina (4), I.V. Kolyadina (5), K.A. Vorontsova (1), O.V. Sekhina (1), K.S. Grechukhina (1)
Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer57-65
M.A. Dzhelyalova, V.F. Semiglazov
Ways to improve endocrine therapy in postmenopausal women with ER+/HER2- breast cancer66-69
ORIGINAL ARTICLES
G.A. Khakimov (1, 2), B.B. Negmadzhanov (3), G.G. Khakimova (1, 2), M.N. Tashmetov (1), Kh.U. Musurmonov (1, 2), Sh.G. Khakimova (1, 4), Sh.Sh. Kadyrov (1, 2), Sh.T. Usmanova (1, 2)
Radical hysterectomy with adequate dissection of areas of possible metastasis in locally advanced cervical cancer70-76
D.V. Ivashchenko (1, 2), N.I. Buromskaya (3), P.V. Shimanov (3), R.V. Deich (3), I.V. Dorina (3), M.I. Nastovich (3), K.A. Akmalova (1), A.A. Kachanova (1), E.A. Grishina (1), L.M. Savchenko (1), Yu.S. Shevchenko (1), D.A. Sychev (1)
Pharmacogenetic predictors of the efficacy and safety of antipsychotics in adolescents with an acute psychotic episode77-83
D.A. Sychev (1), O.D. Ostroumova (1, 2), A.I. Kochetkov (1), A.P. Pereverzev (1), T.M. Ostroumova (2), M.V. Klepikova (1), E.Yu. Ebzeeva (1)
Medication errors as risk factor for drug-induced diseases84-94
S.V. Khokhlova
Clinical case of treatment of patient with HRD-positive ovarian cancer96-104
M.M. Konstantinova (1), L.I. Kuzina (2)
Will our clinical practice change with the availability of new diagnostic methods, drug therapy and assessment of its effectiveness? Clinical case: hormone receptor-positive, HER2-negative metastatic breast cancer105-110
Kh.I. Dzhumaniezov (1, 2), G.A. Khakimov (1, 2), G.G. Khakimova (1, 2), Sh.T. Usmanova (1, 2), Sh.G. Khakimova (1, 3), Sh.Sh. Kadyrov (1, 2)
Clinical observation of successful treatment of retroperitoneal nephroblastoma111-114
115
